ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Sep 16, 2017
Valuentum's September Edition of Its Best Ideas Newsletter
The link to download the September edition of the Best Ideas Newsletter can be found in this article.
Sep 13, 2017
Earnings Snapshot: Cracker Barrel’s Hidden 5%+ Dividend Yield
Cracker Barrel is holding its share-price uptrend nicely. The company is one of our favorite restaurants thanks in part to its differentiated niche and country store concept. Special dividend payouts make it a hidden income gem, in our view.
Sep 11, 2017
Canakinumab Posts Some Impressive Data For Novartis
Image Source: Novartis. We remain impressed with the depth of the clinical pipeline that is currently being brought out to market by the Dividend Growth Newsletter portfolio idea Novartis. We closely follow the data delivered from clinical trials to gauge the potential for the pipeline; in the case of Novartis, we feel the strength of the emerging pipeline bodes very well for continued dividend growth over the next few years. In this piece, we will detail the clinical results for Canakinumab, as we feel the molecule will nicely complement Novartis’ burgeoning cardiovascular unit.
Sep 9, 2017
Fair Value Estimates of Stocks In Our Coverage Universe
In this article, use the download to view the fair value estimates of companies in our coverage universe.
Sep 9, 2017
Rank Our Coverage Universe By Valuentum Buying Index Rating
Use the download in this article to rank our coverage universe by each firm's respective Valuentum Buying Index rating.
Sep 5, 2017
Gilead Sciences Finally Takes Out A Promising Biotech
Image Source: Gilead. We are pleased to see that Gilead Sciences has decided to put its vast cash hoard to use by acquiring a cutting-edge technology that will further its clinical pipeline.
Sep 1, 2017
ETF Analysis: Industrials
Industrial sector ETFs offer greater diversification than just “old-economy” companies, and exposure to the sustainable strength of aerospace makes several worth considering.
Aug 31, 2017
Gilead's Stock Rockets Higher
Gilead’s stock is soaring on a technical breakout of the downtrend. Value investors have joined the party, too, as the hepatitis-C powerhouse remains undervalued on our discounted cash-flow process. When value and technical/momentum investors like the same stock, it often surges, and that’s what we’re witnessing. Gilead has become a Valuentum stock.
Aug 18, 2017
CVS Health Still Stuck in Neutral
Image Source: CVS Health. CVS Health continues to perform as expected in the current lower reimbursement environment. We remain enthused with the copious amount of free cash flow that the enterprise produces, which has allowed management to continue its shareholder-friendly ways. We remain vigilant for signs of a key inflection point, however, and a catalyst may exist in the results of the current PBM selling season.
Aug 17, 2017
Recent Stock Drops; Dividend Cut Coming at Plains?
Image Shown: Plains All American's stock price may be building in a distribution cut that may materialize in the near term. Several companies disappointed the Street as of late. Though the broader equity markets have been generally calm and steadily-advancing, some underlying constituents have been anything but.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.